ScholarIQanswers from OpenAlex & ORCID
Tae Won Kim
ResearcherPublications, citations & collaboration network
Tae Won Kim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Tae Won Kim have?
ScholarIQindexed works
Tae Won Kim has 474 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tae Won Kim have?
ScholarIQcitation count
Tae Won Kim has 17,844 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Tae Won Kim?
ScholarIQh-index
Tae Won Kim has an h-index of 58 in OpenAlex.
What is the i10-index of Tae Won Kim?
ScholarIQi10-index
Tae Won Kim has an i10-index of 218 in OpenAlex.
What is the ORCID of Tae Won Kim?
ScholarIQorcid
The ORCID for Tae Won Kim is on the source record.
What is the OpenAlex record for Tae Won Kim?
ScholarIQopenalex
The OpenAlex for Tae Won Kim is on the source record.
What are the most-cited papers on Tae Won Kim?
ScholarIQmost cited works
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Rui‐Hua Xu, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, Masato Nakamura, Joong Bae Ahn, Yan‐Hong Deng, Takeshi Kato, Sang‐Hee Cho, Yi Ba, Hiroshi Matsuoka, Keun‐Wook Lee, Tao Zhang, Yasuhide Yamada, Junichi Sakamoto, Young Suk Park, Tae Won Kim
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, Bu Man Park, Eunhye Park, Jong Hwan Bae, Chang‐Min Choi, Jae Cheol Lee